Actively Recruiting
Study of Atrial Fibrillation Combined with Atrial Functional Mitral Regurgitation
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2024-11-22
500
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the improvement of mitral regurgitation after catheter ablation of atrial fibrillation or regular drug therapy in atrial fibrillation patients combined with atrial functional mitral regurgitation.
CONDITIONS
Official Title
Study of Atrial Fibrillation Combined with Atrial Functional Mitral Regurgitation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 to 80 years old
- Diagnosed with symptomatic paroxysmal atrial fibrillation with history less than 5 years
- Moderate to severe mitral regurgitation with normal left ventricular ejection fraction (≥50%)
- Left ventricular end-diastolic diameter less than 55 mm and normal left ventricular wall systolic function
- Able to understand the trial purpose and voluntarily provide signed informed consent
- Willing to complete all follow-up visits as required by the study protocol
You will not qualify if you...
- Atrial fibrillation caused by reversible factors like electrolyte imbalances or thyroid disease
- Active endocarditis, active rheumatic heart disease, or degenerative mitral regurgitation from these causes
- Moderate to severe mitral stenosis
- Presence of left atrium or left atrial appendage thrombosis on imaging
- Left ventricular ejection fraction below 50%
- Left atrial diameter greater than 50 mm
- Previous left atrial appendage occlusion or closure, patent foramen ovale closure, atrial septal defect closure or repair (if ablation needed)
- Implanted devices such as ICD, CRT, or pacemaker
- Previous metal artificial valve or valve repair device implantation (if ablation needed)
- Lateral thrombus, tumors, or abnormalities interfering with catheter operation (if ablation needed)
- Contraindications to anticoagulation or history of clotting or bleeding disorders
- Acute systemic infection
- Female patients who are pregnant, lactating, or unable to use contraception during the study
- Life expectancy less than 12 months
- Any abnormalities or diseases deemed unsuitable for study participation by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Second Affiliated Hospital of Zhejiang University, School of Medicine
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
Research Team
X
Xianbao Liu, Dorctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here